China Pharma Holdings (CPHI) Revenue (2010 - 2026)
China Pharma Holdings (CPHI) posted Revenue of $983536.0 for Q1 2026, down 19.78% on a QoQ basis from $1.2 million in Q4 2025, and down 13.44% year-over-year from $1.1 million in Q1 2025.
China Pharma Holdings (CPHI) Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings' Revenue history runs 17 years deep, the most recent figure standing at $983536.0 for Q1 2026.
- Quarterly Revenue fell 13.44% year-over-year to $983536.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 7.07% YoY) and the FY2025 annual result came in at $4.1 million, down 8.49% from the prior year.
- Revenue was $983536.0 for Q1 2026 at China Pharma Holdings, down from $1.2 million in the prior quarter.
- Across five years, Revenue topped out at $2.9 million in Q4 2022 and bottomed at $756217.0 in Q3 2025.
- A 5-year average of $1.5 million and a median of $1.2 million in 2025 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue rose 22.21% — and 2024, when it plunged 47.25%.
- China Pharma Holdings' Revenue stood at $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then sank by 47.25% to $1.1 million in 2024, then grew by 8.11% to $1.2 million in 2025, then retreated by 19.78% to $983536.0 in 2026.
- Business Quant data shows CPHI's Revenue at $983536.0 in Q1 2026, $1.2 million in Q4 2025, and $756217.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 3.98 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 2.26 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 6.98 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 781.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 3.51 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 814.50 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 1.37 Bn |
| 10 | China Pharma Holdings | 40.71 Mn | 40.54 Mn | 285,487.00 | 983,536.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 983,536.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 756,217.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 924,943.00 |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 1.80 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 1.61 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 2.89 Mn |
| Sep 30, 2021 | 1.98 Mn |
| Jun 30, 2021 | 2.42 Mn |